New Edison report. Their valuation now $2.10
https://www.edisongroup.com/publication/all-in-on-gbm-agile-but-eyes-on-brain-mets/28944/
https://www.edisongroup.com/wp-content/uploads/2021/03/Kazia-Therapeutics-All-in-on-GBM-AGILE-but-eyes-on-brain-mets.pdf
"We consider brain metastases (BMs) one of the most interesting indications that paxalisib could potentially be used for, and the drug is currently being investigated for this indication in three clinical studies for BMs: one Phase I and two Phase IIs, sponsored by Sloan-Kettering, the NIH and Dana-Farber respectively, all of which are expected to provide data in CY21. In particular we are interested in the product for the treatment of breast cancer brain metastases (BCBMs), which are a major cause of mortality for metastatic breast cancer patients."
- Forums
- ASX - By Stock
- Ann: Kazia licenses Cantrixil to Oasmia
New Edison report. Their valuation now...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)